Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Free Cash Flow (2024 - 2025)

Evommune (EVMN) has disclosed Free Cash Flow for 2 consecutive years, with -$16.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 10.31% to -$16.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$35.1 million, a N/A change, with the full-year FY2025 number at -$76.5 million, down 31.21% from a year prior.
  • Free Cash Flow was -$16.6 million for Q4 2025 at Evommune, up from -$18.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$16.6 million in Q4 2025 to a low of -$18.5 million in Q4 2024.